Themis Medicare Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

Quality Assessment: Persistent Operational Struggles

The quality of Themis Medicare’s business remains a significant concern. The company’s financial performance has been largely flat in the recent quarter ending December 2025, with operating profit declining at an alarming annualised rate of -185.54% over the past five years. This stark contraction highlights ongoing operational challenges that have yet to be resolved.

Profit after tax (PAT) for the latest six months stood at ₹7.32 crores, reflecting a negative growth rate of -50.60%. Net sales also declined by -20.25% to ₹168.12 crores over the same period. The return on capital employed (ROCE) for the half-year was a negative -3.47%, underscoring the company’s inability to generate adequate returns on its invested capital. Furthermore, Themis Medicare recorded a negative EBITDA of ₹-9.18 crores, signalling cash flow pressures and operational inefficiencies.

These metrics collectively contribute to a low Mojo Score of 31.0 and a Mojo Grade of Sell, a modest improvement from the previous Strong Sell rating but still indicative of subpar business quality.

Valuation: Risky and Below Historical Averages

From a valuation standpoint, Themis Medicare remains a risky proposition. The stock is classified as a micro-cap, trading at ₹80.45 as of the latest close, significantly below its 52-week high of ₹179.25. Over the past year, the stock has delivered a negative return of -42.62%, underperforming the broader Sensex, which declined by only -1.67% in the same period.

Despite the company’s small size, domestic mutual funds hold no stake in Themis Medicare, suggesting a lack of institutional confidence. This absence of mutual fund ownership may reflect concerns about the company’s valuation and business prospects, as these funds typically conduct thorough on-the-ground research before investing.

The stock’s historical valuation multiples appear stretched relative to its earnings and cash flow generation, reinforcing the cautious stance among investors and analysts alike.

Financial Trend: Flat to Negative Performance Persists

Themis Medicare’s financial trend remains disappointing, with flat results in the most recent quarter and deteriorating profitability over the medium term. The company’s operating profit has contracted sharply over five years, and recent half-year figures confirm a continuing decline in earnings and sales.

Return metrics such as ROCE remain negative, and the company’s ability to service debt is mixed. While the debt-to-EBITDA ratio is low at -9.15 times, this negative figure reflects the negative EBITDA rather than a strong debt position, signalling financial stress rather than strength.

Long-term returns also paint a bleak picture. Over the last three years, Themis Medicare’s stock has declined by -37.23%, significantly underperforming the BSE500 index, which gained 23.86% in the same period. The one-year return of -42.62% further emphasises the company’s struggles to generate shareholder value.

Technicals: Signs of Mild Improvement Drive Upgrade

The primary catalyst for the upgrade from Strong Sell to Sell is a shift in technical indicators, which have moved from a bearish to a mildly bearish stance. Weekly technical signals have improved, with the MACD showing a mildly bullish trend and the KST indicator also turning mildly bullish on a weekly basis. The Dow Theory weekly trend has shifted to mildly bullish, suggesting some positive momentum in the near term.

However, monthly technicals remain bearish or neutral, with the MACD and KST indicators still negative and no clear trend on the On-Balance Volume (OBV) or Relative Strength Index (RSI). Daily moving averages continue to signal bearishness, indicating that the stock has yet to establish a sustained upward trend.

Price action supports this mixed technical picture. The stock closed at ₹80.45 on 7 April 2026, up 1.84% from the previous close of ₹79.00, with intraday trading ranging between ₹77.15 and ₹81.00. Despite this modest uptick, the stock remains well below its 52-week high of ₹179.25, reflecting ongoing volatility and investor caution.

Comparative Performance: Underperformance Against Benchmarks

When benchmarked against the Sensex, Themis Medicare’s returns have been inconsistent and largely disappointing. The stock outperformed the Sensex over the past week with a 22.13% gain compared to the Sensex’s 3.00%, and marginally over the past month with a 1.77% gain versus the Sensex’s -6.10% decline. However, year-to-date and longer-term returns tell a different story.

Year-to-date, the stock has fallen by -20.07%, underperforming the Sensex’s -13.04%. Over one year, the stock’s return of -42.62% starkly contrasts with the Sensex’s modest decline of -1.67%. The three-year return of -37.23% is particularly concerning when compared to the Sensex’s robust 23.86% gain, highlighting the company’s sustained underperformance.

Despite a strong five-year return of 162.05%, which outpaces the Sensex’s 50.62%, the recent negative trends overshadow this longer-term gain. The ten-year return of 121.50% trails the Sensex’s 197.61%, indicating that the company’s growth has lagged broader market indices over the last decade.

Outlook and Investor Considerations

The upgrade to a Sell rating reflects a cautious optimism driven by technical improvements, but fundamental and valuation concerns remain significant. Investors should weigh the modest technical momentum against the company’s weak financial trends, negative profitability, and valuation risks.

Themis Medicare’s micro-cap status and lack of institutional ownership further suggest that the stock may not yet be ready for a sustained recovery. The company’s negative EBITDA and poor return metrics indicate operational challenges that require resolution before a more positive outlook can be established.

For investors seeking exposure to the pharmaceuticals and biotechnology sector, Themis Medicare currently presents a high-risk profile with limited near-term catalysts for turnaround. Monitoring technical indicators may provide short-term trading opportunities, but a fundamental improvement is necessary for a more favourable long-term investment case.

Summary

Themis Medicare Ltd’s investment rating upgrade from Strong Sell to Sell is primarily driven by a shift in technical indicators from bearish to mildly bearish, signalling tentative positive momentum. However, the company’s financial performance remains flat to negative, with declining profits, negative EBITDA, and poor return ratios. Valuation concerns persist, compounded by the absence of institutional ownership and underperformance relative to market benchmarks. Investors should approach the stock with caution, balancing the technical signals against the company’s fundamental challenges.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today